Physician profile
Michael Lamonica
NPI 1861471609
$3,418.36
in general payments reported to CMS, 2019-2025
20 companies · $708 in 2025
The $708 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $161 · 2021: $98.00 · 2022: $566 · 2023: $956 · 2024: $431 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.65 | 2022-2025 | |
| Heru, INC. | $674.96 | 2023 | Heru Hmd |
| Allergan, INC. | $273.84 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $180.58 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $155.51 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.29 | 2019-2020 | |
| Alcon Vision LLC | $139.59 | 2022-2025 | Simbrinza, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $132.74 | 2019-2022 | |
| Sight Sciences, INC. | $122.69 | 2022-2025 | Omni Surgical System |
| Amgen INC. | $116.03 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $91.41 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $80.66 | 2022-2024 | Miebo, Xiidra |
| Glaukos Corporation | $67.43 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Shire North American Group INC | $66.01 | 2019 | |
| Biotissue Holdings INC. | $58.07 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $57.06 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $42.67 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $28.67 | 2020-2021 | |
| Dompe US, INC. | $27.85 | 2025 | Oxervate |
| Astellas Pharma US INC | $25.65 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lamonica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.